SLS — what changed in the latest 10-Q
A section-by-section comparison of SLS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-11 vs the prior 10-Q · 2026-05-12
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +20 | −10 | ~22 | 30 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 20 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 20 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 20 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 20 |
| Other information | No paragraph-level changes | 0 | 0 | 0 | 20 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-11
Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product
candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product cand…
•$0.6 million of increased external clinical trial expenses related to SLS009 driven by the timing of enrollment in our randomized Phase 2 clinical trial of newly diagnosed, front-line AML patients;
Research and development expenses were $11.4 million for the six months ended June 30, 2026 compared to $7.1 million for the six months ended June 30, 2025.
The increase in research and development expenses of approximately $4.3 million was primarily attributable to the following:
Text removed vs the prior filing · source: 10-Q · 2026-05-12
In December 2020, we entered into an exclusive license agreement, or the 3D Medicines Agreement, with 3D Medicines Inc., or 3D Medicines, a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as our next ge…
and milestone payments under our license agreement with 3D Medicines, or the 3D Medicines Agreement, and a total of $191.5 million in potential future development, regulatory and sales milestones, not including future royalties, remains under the license agreement, which milestones are variable in n…
Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to disc…
•$0.2 million of decreased external clinical trial expenses related to SLS009 driven by the timing of patient enrollment as we commenced a randomized Phase 2 clinical trial of newly diagnosed, front-line AML patients at the end of the current period.
Non-operating income of $0.8 million and $0.3 million during the three months ended March 31, 2026 and 2025, respectively, was related to interest income earned from our cash and cash equivalents.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice